具有活化且类耗竭表型的人效应 CD8(+) T 细胞在人源化肿瘤模型中体内控制肿瘤生长

Humanized tumour models could be particularly valuable for cancer immunotherapy research, as they may better reflect human-specific aspects of the interfaces between tumour and immune system of human cancer. However, endogenous antitumour immunity in humanized models is still largely undefined.

We established an autologous humanized mouse tumour model by using NSG mice reconstituted with human immune cells from hematopoietic progenitors and tumours generated from transformed autologous human B cells. We demonstrate growth of solid lymphoid tumours after subcutaneous implantation, infiltration by endogenous human immune cells and immunocompetence of the model.

We found human T cell subsets described in human cancer, including progenitor exhausted (T pex ), terminally exhausted (T ex-term ) and tissue-resident (T RM ) cells in tumour-bearing humanized mice with accumulation of T ex-term and T RM in the tumour. In addition, we identified tumour-reactive CD8 + T cells through expression of CD137. This subpopulation of de novo arising human CD137 + CD8 + T cells displayed a highly proliferative, fully activated effector and exhausted-like phenotype with enhanced expression of activation and exhaustion markers like PD-1, CD39, CD160, TIM-3, TIGIT and TOX, the senescence marker CD57 (B3GAT1) and cytolytic effector molecules such as PRF1, GZMH and NKG7. Moreover, these CD137 + CD8 + T cells exhibited tumour-specific clonal expansion and presented signature overlap with tumour-reactive CD8 + T cells described in human cancer. We demonstrate superior anticancer activity of this activated and exhausted-like human CD8 + T cell subset by adoptive transfer experiments using recipients bearing autologous human tumours. Mice adoptively transferred with CD137 + CD8 + T cells showed reduced tumour growth and higher CD8 + T cell tumour infiltration, correlating with control of human tumours. INTERPRETATION: We established an immunocompetent humanized tumour model, providing a tool for immunotherapy research and defined effective anticancer activity of human effector CD8 + T cells with an activated and exhausted-like phenotype, supporting clinical exploration of such cells in adoptive T cell therapies. FUNDING: Swiss Cancer Research foundation.